Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by RAYMOND E SAWAYA and GREGORY N FULLER.
RAYMOND E SAWAYA
Connection Strength
2.155
GREGORY N FULLER
  1. Response of treatment-naive brain metastases to stereotactic radiosurgery. Nat Commun. 2024 May 02; 15(1):3728.
    View in: PubMed
    Score: 0.247
  2. Subependymomas of the fourth ventricle: To operate or not to operate? J Clin Neurosci. 2023 Dec; 118:147-152.
    View in: PubMed
    Score: 0.239
  3. Magnetic resonance imaging features of pilocytic astrocytoma of the brain mimicking high-grade gliomas. J Comput Assist Tomogr. 2010 Jul; 34(4):601-11.
    View in: PubMed
    Score: 0.095
  4. Surgical management of lateral-ventricle metastases: report of 29 cases in a single-institution experience. J Neurosurg. 2010 May; 112(5):1046-55.
    View in: PubMed
    Score: 0.094
  5. The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor. Clin Neurosurg. 2009; 56:98-106.
    View in: PubMed
    Score: 0.085
  6. Origin of chordoid glioma of the third ventricle. Arch Pathol Lab Med. 2006 Apr; 130(4):460-4.
    View in: PubMed
    Score: 0.071
  7. Pineal cyst apoplexy: case report and review of the literature. Neurosurgery. 2005 Nov; 57(5):E1066; discussion E1066.
    View in: PubMed
    Score: 0.069
  8. Molecular voting for glioma classification reflecting heterogeneity in the continuum of cancer progression. Oncol Rep. 2005 Sep; 14(3):651-6.
    View in: PubMed
    Score: 0.068
  9. Many human medulloblastoma tumors overexpress repressor element-1 silencing transcription (REST)/neuron-restrictive silencer factor, which can be functionally countered by REST-VP16. Mol Cancer Ther. 2005 Mar; 4(3):343-9.
    View in: PubMed
    Score: 0.065
  10. Correction: Detecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients. J Transl Med. 2024 Mar 21; 22(1):296.
    View in: PubMed
    Score: 0.061
  11. Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):212-21.
    View in: PubMed
    Score: 0.060
  12. Cystic glioblastoma multiforme: survival outcomes in 22 cases. J Neurosurg. 2004 Jan; 100(1):61-7.
    View in: PubMed
    Score: 0.060
  13. Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery. 2002 Jul; 51(1):2-12; discussion 12-3.
    View in: PubMed
    Score: 0.054
  14. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncol. 2022 06 01; 11(2):CNS87.
    View in: PubMed
    Score: 0.054
  15. Imaging characteristics of 4th ventricle subependymoma. Neuroradiology. 2022 Sep; 64(9):1795-1800.
    View in: PubMed
    Score: 0.054
  16. Long term outcomes following surgery for pineal region tumors. J Neurooncol. 2022 Feb; 156(3):491-498.
    View in: PubMed
    Score: 0.053
  17. Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol. 2002 Jan; 12(1):108-16.
    View in: PubMed
    Score: 0.053
  18. A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdaa146.
    View in: PubMed
    Score: 0.048
  19. Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. JCI Insight. 2020 09 03; 5(17).
    View in: PubMed
    Score: 0.048
  20. Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res. 2020 07 15; 26(14):3565-3577.
    View in: PubMed
    Score: 0.047
  21. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
    View in: PubMed
    Score: 0.047
  22. A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models. Clin Cancer Res. 2018 12 15; 24(24):6288-6299.
    View in: PubMed
    Score: 0.041
  23. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J Clin Oncol. 2018 05 10; 36(14):1419-1427.
    View in: PubMed
    Score: 0.040
  24. Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology. 2018; 7(4):e1412909.
    View in: PubMed
    Score: 0.040
  25. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016; 1(2).
    View in: PubMed
    Score: 0.035
  26. Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. J Neurosci. 2015 Nov 11; 35(45):15097-112.
    View in: PubMed
    Score: 0.034
  27. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma. Acta Neuropathol. 2015 Oct; 130(4):587-97.
    View in: PubMed
    Score: 0.034
  28. Therapeutic targets in subependymoma. J Neuroimmunol. 2014 Dec 15; 277(1-2):168-75.
    View in: PubMed
    Score: 0.032
  29. Transcriptome and small RNA deep sequencing reveals deregulation of miRNA biogenesis in human glioma. J Pathol. 2013 Feb; 229(3):449-59.
    View in: PubMed
    Score: 0.028
  30. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest. 2013 Feb; 123(2):855-65.
    View in: PubMed
    Score: 0.028
  31. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res. 2010 Dec 01; 16(23):5722-33.
    View in: PubMed
    Score: 0.024
  32. yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients. J Transl Med. 2009 Nov 09; 7:92.
    View in: PubMed
    Score: 0.023
  33. IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proc Natl Acad Sci U S A. 2009 Sep 29; 106(39):16675-9.
    View in: PubMed
    Score: 0.022
  34. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res. 2008 Dec 15; 14(24):8228-35.
    View in: PubMed
    Score: 0.021
  35. Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics. 2006 May; 6(10):2964-71.
    View in: PubMed
    Score: 0.018
  36. The SHREW1 gene, frequently deleted in oligodendrogliomas, functions to inhibit cell adhesion and migration. Cancer Biol Ther. 2006 Mar; 5(3):300-4.
    View in: PubMed
    Score: 0.018
  37. Attenuated expression of DFFB is a hallmark of oligodendrogliomas with 1p-allelic loss. Mol Cancer. 2005 Sep 12; 4:35.
    View in: PubMed
    Score: 0.017
  38. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst. 2003 May 07; 95(9):652-60.
    View in: PubMed
    Score: 0.014
  39. Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neuro Oncol. 2002 10; 4(4):268-77.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.